BUND FINANCE

BUND FINANCE › Stocks › LLY

Eli Lilly and Company (LLY)

NYSE · Stock price, chart and technical analysis

US$1,351.12-31.63 (-2.29%)

Data from Financial Modeling Prep · Nov 19, 2026, 4:02 PM New York time · may be delayed

Open the live chartSee Technicals⏱ Analyze entryQuarterly earnings📅 See in calendar💬 Explain this move⇄ ComparePractice in the Simulator

Key stats

Previous closeUS$1,382.75
OpenUS$1,369.38
Day rangeUS$1,341.46 – US$1,382.00
52-week rangeUS$850.51 – US$1,475.25
Market capUS$1.27T
Volume3.07M
50-day averageUS$1,257.73
200-day averageUS$1,115.05
Beta0.45
Last dividend per shareUS$6.92

Quick technical read

This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it

Fundamentals Annual

Fiscal year20212022202320242025
RevenueUS$28.3BUS$28.5BUS$34.1BUS$45.0BUS$65.2B
Net incomeUS$5.6BUS$6.2BUS$5.2BUS$10.6BUS$20.6B
EPS (diluted)6.126.905.8011.7122.95
Gross margin74.2%76.8%79.3%81.3%83.0%
Operating margin22.5%25.0%31.6%37.8%45.6%
Net margin19.7%21.9%15.4%23.5%31.7%
Free cash flowUS$5.4BUS$4.6BUS$792.5MUS$3.8BUS$9.0B
Total debtUS$16.9BUS$16.2BUS$25.2BUS$33.6BUS$42.5B
CashUS$3.8BUS$2.1BUS$2.8BUS$3.3BUS$7.3B

Compound annual growth: revenue 23.2% · net income 38.7% (4 years).

Valuation: today, its history and its sector

Today5-year averageSector median (Healthcare)
P/E43.9x62.0x26.4x
EV / EBITDA29.4x41.3x16.3x
Operating margin46.1%—3.6%
Net margin31.9%—-0.0%
Debt / equity2.68—0.58

Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.

About Eli Lilly and Company

SectorHealthcare
IndustryDrug Manufacturers - General
CountryUS
CEODavid A. Ricks
Employees50,000
IPO date1972-06-01

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for n…

www.lilly.com

Other stocks on BUND FINANCE

Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice